RT Journal Article
SR Electronic
T1 Retrospective evaluation of our cohort of CTD-ILD RA patients treated with Rituximab: 5 years follow up
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2373
DO 10.1183/13993003.congress-2021.PA2373
VO 58
IS suppl 65
A1 Francesco Bini
A1 Angelo De Lauretis
A1 Cristina Arosio
A1 Bruno Dino Bodini
A1 Stefano Carlo Zucchetti
A1 Maria Chiara Papetti
A1 Adriano Vaghi
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA2373.abstract
AB Rheumatoid arthritis (RA) can affect the lung, with different types of involvement: sometimes a radiological fibrotic pattern such as Usual Interstitial Pneumoniae (UIP) can develop.Chest CT scan is completely indistinguishable from that of idiopathic pulmonary fibrosis (IPF), with honeycombing and traction bronchiectasis, although some reports seem to show that pulmonary fibrosis cysts of RA patients are larger than those of IPF patients.In RA patients with UIP pattern (connective-tissue-disease/interstitial-lung-disease, CTD-ILD), studies show a severe prognosis in the medium term, only slightly better than the idiopathic form of fibrotic pulmonary involvement.We assessed the clinical and functional trend of patients with CTD-ILD due to RA treated with Rituximab in our center. We reached 5 years of follow up.We have enrolled 26 patients. Multidisciplinary group diagnosis was made. Patients received Rituximab therapy, 1,000 mg for 2 administrations. TimeN. patientsFVC% predictedTLC% predictedDLCO% predicted6mWTCD19+Lymphocytes on BAL % Baseline 2671774440114.836 6 months 267479584350.011.2 12 months 2576796142224.8 24 months 247680594287.410.1 36 months 167577604209.112.2 48 monhths 870725340915.018.6 60 months 267684739016.721.3The patients showed only 1 episode of complication, an immune complex reaction at the level of the shoulder girdle, which resolved itself and which did not prevent a second treatment.Conclusions: Rituximab has been shown to be safe with only one mild adverse reaction episode. Breath tests show stability with tendency to improve until 3 years and a slight reduction after it. We are still studying the cohort.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2373.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).